A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Publication | Closed Access

DOI

Citations

References

2016

Year

Tamás Pintér, Zandra Klippel, Alvydas Česas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, G. Kurteva, Jan Novotný,

Clinical Colorectal Cancer

Gastrointestinal OncologyMedicinePhase IiiFirst-line Folfox/bevacizumabClinical TrialsColorectal CancerPathologyMetastatic Colorectal CancerCancer TreatmentOncologyRadiation OncologyMolecular OncologyHealth Sciences